Logo

IVVD

Invivyd, Inc.

IVVD

Invivyd, Inc. • NASDAQ
$2.43 ▲ 4.29% (+0.10)
Market Cap $322.53 M
52w High $3.07
52w Low $0.35
Dividend Yield 0%
P/E -5.4
Volume 1.26M
Outstanding Shares 132.73M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.129M ▲ $23.064M ▼ $-10.47M ▲ -79.747% ▲ $-0.06 ▲ $-10.039M ▲
Q2-2025 $11.786M ▲ $26.161M ▼ $-14.66M ▲ -124.385% ▲ $-0.12 ▲ $-14.557M ▲
Q1-2025 $11.304M ▼ $27.392M ▼ $-16.289M ▲ -144.099% ▼ $-0.14 ▲ $-16.184M ▲
Q4-2024 $13.82M ▲ $32.325M ▼ $-18.443M ▲ -133.452% ▲ $-0.15 ▲ $-17.713M ▲
Q3-2024 $9.3M $70.805M $-60.739M -653.108% $-0.51 $-61.752M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $84.967M ▲ $139.158M ▲ $46.09M ▼ $93.068M ▲
Q2-2025 $34.905M ▼ $89.138M ▼ $46.349M ▼ $42.789M ▼
Q1-2025 $48.078M ▼ $103.744M ▼ $49.595M ▼ $54.149M ▼
Q4-2024 $69.349M ▼ $129.515M ▼ $61.976M ▼ $67.539M ▼
Q3-2024 $106.869M $161.922M $78.761M $83.161M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-10.47M ▲ $-8.25M ▲ $0 ▲ $58.312M ▲ $50.062M ▲ $-8.25M ▲
Q2-2025 $-14.66M ▲ $-13.301M ▲ $-11K ▲ $131K ▲ $-13.173M ▲ $-13.312M ▲
Q1-2025 $-16.289M ▲ $-21.129M ▲ $-144K ▼ $10K ▼ $-21.271M ▲ $-21.273M ▲
Q4-2024 $-18.443M ▲ $-37.61M ▲ $5K ▲ $77K ▲ $-37.52M ▲ $-37.605M ▲
Q3-2024 $-60.739M $-41.068M $-5K $61K $-41.012M $-41.073M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Invivyd is still very much in the development stage financially. Revenue has been essentially zero over the past several years, with only a very small amount starting to appear recently, likely tied to its first authorized product. Operating losses have been consistent and sizable each year, reflecting heavy spending on research, clinical trials, and infrastructure without material commercial sales yet. Net losses per share have been large but show a mild improving trend most recently, suggesting some cost discipline, early revenue, or both. Overall, the business is still investing heavily ahead of meaningful scale, and profitability is not yet in sight.

Balance Sheet

Balance Sheet The balance sheet shows a company funded primarily by equity, with no recorded debt, which reduces financial leverage risk but puts the emphasis on shareholder dilution as the main funding tool. Cash once represented the bulk of total assets and was at its strongest shortly after going public, but it has been drawn down over time as operating losses accumulated. Total assets and equity have both declined from earlier peaks, signaling that the company is using past capital raises to fund ongoing R&D and operations. While the lack of debt is a positive, the shrinking asset and cash base underscore that Invivyd depends on either new capital infusions or a ramp-up in product revenues to sustain its roadmap.

Cash Flow

Cash Flow Cash flow patterns are typical of a clinical‑stage biotech: operating cash flow has been negative every year, broadly matching the size of reported losses. Free cash flow is also negative and nearly identical to operating cash flow, as capital spending is minimal—most cash is going straight into people, trials, and platform development rather than physical assets. The level of cash burn has been fairly steady over the years, indicating a consistent pace of investment rather than sudden surges. This reinforces that the company’s current model is to consume cash while it develops its pipeline, with future product approvals and partnerships being key to eventually shifting toward self-sustaining cash generation.

Competitive Edge

Competitive Edge Invivyd competes in a crowded and fast-moving part of biotech but has carved out a clear niche. Its focus on monoclonal antibodies for infectious diseases—especially for immunocompromised patients who may not respond well to vaccines—targets a specific, underserved population. The INVYMAB platform aims to move faster than viral evolution, which, if it works as intended, could be a meaningful edge versus slower, more traditional development approaches. Having an authorized COVID‑19 prophylactic product and an emerging next‑generation candidate gives it real‑world validation and a foothold with regulators and clinicians. That said, the company faces competition from large pharmaceutical firms with deep resources, as well as from vaccines, small‑molecule antivirals, and other antibody developers. Its position is promising but still early, and it will need clinical success, regulatory clarity, and commercial uptake to turn its technological edge into durable market share.

Innovation and R&D

Innovation and R&D Innovation is the core of Invivyd’s story. The INVYMAB platform integrates viral surveillance, predictive modeling, and advanced antibody engineering, aiming to quickly generate new antibodies as viruses mutate. This is particularly important for diseases like COVID‑19, where older antibodies can rapidly lose effectiveness. Beyond its first COVID antibody (PEMGARDA) and a more potent, longer‑lasting follow‑on candidate (VYD2311), the company is pushing into other major viral threats such as RSV, measles, and influenza, and even exploring applications in Long COVID. Many of these programs are still early or preclinical, which brings high uncertainty but also significant upside potential if they progress. Overall, Invivyd is clearly R&D‑driven, with its value tied to whether this pipeline can translate from promising science into approved, widely used products.

Summary

Invivyd is a classic high‑risk, innovation‑driven biotech: it has significant scientific ambition, a focused infectious‑disease platform, and early regulatory traction, but it remains in the loss‑making, cash‑consuming phase with only nascent revenue. Financially, the company has no debt and relies on equity funding, while steadily drawing down its cash as it invests in R&D and clinical programs. Strategically, it is differentiated by its rapid‑response antibody platform and its emphasis on vulnerable patient groups, with a pipeline that stretches from COVID‑19 into RSV, measles, and flu. The main uncertainties lie in clinical outcomes, regulatory decisions, the pace of real‑world adoption, and the company’s ability to secure sufficient funding before its products can materially support the business. In short, Invivyd offers a compelling scientific platform coupled with meaningful financial and execution risk, typical of an early‑stage biotech focused on infectious diseases.

NEWS

November 25, 2025 · 7:01 AM UTC

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference

Read more

November 24, 2025 · 7:01 AM UTC

Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Read more

November 17, 2025 · 10:40 PM UTC

Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants

Read more

November 17, 2025 · 4:01 PM UTC

Invivyd Announces Proposed Public Offering of Common Stock

Read more

November 6, 2025 · 7:01 AM UTC

Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Read more